Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 427-433

  Rieder, Simon ^a   Michalski, Christoph W ^a   Friess, Helmut ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Igf 1; Mtor; Pancreatic cancer

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; AG 538; AMG 479A; ANTINEOPLASTIC AGENT; AVE 1642; BMS 754807; CAMPTOTHECIN; CARBOPLATIN; CIXUTUMUMAB; DALOTUZUMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; GANITUMAB; GEMCITABINE; INSM 18; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MONOCLONAL ANTIBODY; NVP AEW 541; PACLITAXEL; PANITUMUMAB; PICROPODOPHYLLIN; R 1507; RIDAFOROLIMUS; SOMATOMEDIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 228;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL PROLIFERATION; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EWING SARCOMA; FATIGUE; GENE OVEREXPRESSION; HUMAN; HYPERGLYCEMIA; LUNG NON SMALL CELL CANCER; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 79958106621     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677454     Document Type: Article

References (64)

1. Wang, Y.; Sun, Y. Insulin-like growth factor receptor-1 as an anti- cancer target: blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets, 2002, 2(3), 191-207.
2. Dunn, S.E.; Kari, F.W.; French, J.; Leininger, J.R.; Travlos, G.; Wilson, R.; Barrett, J.C. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res, 1997, 57(21), 4667-4672.
3. Baserga, R.; Hongo, A.; Rubini, M.; Prisco, M.; Valentinis, B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta, 1997, 1332(3), F105-126.
4. Pandini, G.; Frasca, F.; Mineo, R.; Sciacca, L.; Vigneri, R.; Belfiore, A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem., 2002, 277(42), 39684-39695.
5. Baxter, R.C. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab., 2000, 278(6), E967-976.
6. Mohan, S.; Baylink, D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol., 2002, 175(1), 19-31.
7. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev, 2004. 18(16), 1926-1945.
8. Bjornsti, M.A.; Houghton, P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer, 2004, 4(5), 335-348.
9. Sabatini, D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer, 2006, 6(9), 729-734.
10. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66(3), 1500-1508.
11. Pollak, M.N.; Perdue, J.F.; Margolese, R.G.; Baer, K.; Richard, M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett., 1987, 38(1-2), 223-230.
12. Chan, J.M.; Stampfer, M.J.; Giovannucci, E.; Gann, P.H.; Ma, J.; Wilkinson, P.; Hennekens, C.H.; Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 1998, 279(5350), 563-566.
13. Hankinson, S.E.; Willett, W.C.; Colditz, G.A.; Hunter, D.J.; Michaud, D.S.; Deroo, B.; Rosner, B.; Speizer, F.E.; Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 1998, 351(9113), 1393-1396.
14. Ma, J.; Pollak, M.N.; Giovannucci, E.; Chan, J.M.; Tao, Y.; Hennekens, C.H.; Stampfer, M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst., 1999, 91(7), 620-625.
15. Petridou, E.; Dessypris, N.; Spanos, E.; Mantzoros, C., Skalkidou, A., Kalmanti, M., Koliouskas, D., Kosmidis, H., Panagiotou, J.P., Piperopoulou, F., Tzortzatou, F., and Trichopoulos, D. Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int. J. Cancer, 1999, 80(4), 494-496.
16. Bergmann, U.; Funatomi, H.; Yokoyama, M.; Beger, H.G.; Korc, M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res., 1995, 55(10), 2007-2011.
17. Lopez, T.; Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 2002, 1(4), 339-353.
18. Jenkins, P. Cancer in acromegaly. Trends Endocrinol. Metab., 1998, 9(9), 360-366.
19. Dunn, S.E.; Hardman, R.A.; Kari, F.W.; Barrett, J.C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res., 1997, 57(13), 2687-2693.
20. Gooch, J.L.; Van Den Berg, C.L.; Yee, D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects. Breast Cancer Res. Treat, 1999, 56(1), 1-10.
21. Surmacz, E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene, 2003, 22(42), 6589-6597.
22. Kull, F.C.; Jacobs, S.; Su, Y.F.; Svoboda, M.E.; Van Wyk, J.J.; Cuatrecasas, P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J. Biol. Chem., 1983, 258(10), 6561-6566.
23. Arteaga, C.L.; Kitten, L.J.; Coronado, E.B.; Jacobs, S.; Kull, F.C.; Allred, D.C.; Osborne, C.K. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest., 1989, 84(5), 1418-1423.
24. Hofmann, F. and Garcia-Echeverria, C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today, 2005, 10(15), 1041-1047.
25. Weroha, S.J.; Haluska, P. IGF-1 receptor inhibitors in clinical trials--early lessons. J. Mammary Gland Biol. Neoplasia, 2008, 13(4), 471-483.
26. Haluska, P.; Shaw, H.; Batzel, G.N.; Molife, L.R.; Adjei, A.A.; Yap, T.A.; Roberts, M.L.; Gualberto, A.; de Bono, J.S. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. J. Clin. Oncol. (Meeting Abstracts), 2007, 25(18_suppl), 3586.
27. Karp, D.D.; Paz-Ares, L.G.; Novello, S.; Haluska, P.; Garland, L.; Cardenal, F.; Blakely, L.J.; Eisenberg, P.D.; Langer, C.J.; Blumenschein, G.; Johnson, F.M.; Green, S.; Gualberto, A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2009, 27(15), 2516-2522.
28. Sarantopoulos, J.; Mita, A.C.; Mulay, M.; Romero, O.; Lu, J.; Capilla, F.; Chen, L.; Hwang, Y.; Friberg, G.; Rosen, L.S. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J. Clin. Oncol. (Meeting Abstracts), 2008, 26(15_suppl), 3583.
29. Merl, M.Y.; Li, J.; Saif, M.W. The first-line treatment for advanced pancreatic cancer. Highlights from the 2010 ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 22-24, 2010. JOP, 2010, 11(2), 148-150.
30. Philip, P.A.; Goldman, B.H.; Ramanathan, R.K.; Lenz, H.; Lowy, A.M.; Whitehead, R.P.; Iqbal, S.; Chung, V.M.; Benedetti, J.K.; Blanke, C.D. SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. J. Clin. Oncol., (Meeting Abstracts), 2010, 28(15_suppl), TPS223.
31. Kurzrock, R.; Patnaik, A.; Aisner, J.; Warren, T.; Leong, S.; Benjamin, R.; Eckhardt, S.G.; Eid, J.E.; Greig, G.; Habben, K.; McCarthy, C.D.; Gore, L. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res., 2010, 16(8), 2458-2465.
32. Tolcher, A.W.; Patnaik, A.; Till, E.; Takimoto, C.H.; Papadopoulos, K.P.; Massard, C.; Mery-Mignard, D.; Deslandes, A.; Ozoux, M.; Soria, J. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST). J Clin Oncol (Meeting Abstracts), 2008, 26(15_suppl), 3582.
33. Javle, M.M.; Varadhachary, G.R.; Shroff, R.T.; Bhosale, P.; Overman, M.J.; Weatherly, J.; Wolff, R.A.; Abbruzzese, J.L. Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J. Clin. Oncol. (Meeting Abstracts), 2010, 28(15_suppl), 4039.
34. Ullrich, A.; Gray, A.; Tam, A.W.; Yang-Feng, T.; Tsubokawa, M.; Collins, C.; Henzel, W.; Le Bon, T.; Kathuria, S.; Chen, E.; and et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J, 1986. 5(10), 2503-2512.
35. Garber, K. IGF-1: old growth factor shines as new drug target. J. Natl. Cancer Inst., 2005, 97(11), 790-792.
36. Parrizas, M.; Gazit, A.; Levitzki, A.; Wertheimer, E.; LeRoith, D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology, 1997, 138(4), 1427-1433.
37. Blum, G.; Gazit, A.; Levitzki, A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry, 2000, 39(51), 15705-15712.
38. Garcia-Echeverria, C.; Pearson, M.A.; Marti, A.; Meyer, T.; Mestan, J.; Zimmermann, J.; Gao, J.; Brueggen, J.; Capraro, H.G.; Cozens, R.; Evans, D.B.; Fabbro, D.; Furet, P.; Porta, D.G.; Liebetanz, J.; Martiny-Baron, G.; Ruetz, S.; Hofmann, F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell, 2004, 5(3), 231-239.
39. Scotlandi, K.; Manara, M.C.; Nicoletti, G.; Lollini, P.L.; Lukas, S.; Benini, S.; Croci, S.; Perdichizzi, S.; Zambelli, D.; Serra, M.; Garcia-Echeverria, C.; Hofmann, F.; Picci, P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res., 2005, 65(9), 3868-3876.
40. Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Axelson, M.; Girnita, L.; Larsson, O. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene, 2008, 27(11), 1629-1638.
41. Harzstark, A.L.; Ryan, C.; Diamond, M.; Jones, J.; Zavodovskaya, M.; Maddux, B.; Claros, C.; Goldfine, I.; Small, E.J. A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J. Clin. Oncol. (Meeting Abstracts), 2007, 25(18_suppl), 15500.
42. Lindsay, C.R.; Chan, E.; Evans, T.R.; Campbell, S.; Bell, P.; Stephens, A.W.; Franke, A.; Poondru, S.; Rothenberg, M.L.; Puzanov, I. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts), 2009, 27(15S), 2559.
43. Smith, D.C.; Britten, C.; Clary, D.O.; Nguyen, L.T.; Woodard, P.; Hurwitz, H.I. A phase I study of XL228, a potent IGF1R/ AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J. Clin. Oncol. (Meeting Abstracts), 2009, 27(15S), 3512.
44. Carboni, J.M.; Wittman, M.; Yang, Z.; Lee, F.; Greer, A.; Hurlburt, W.; Hillerman, S.; Cao, C.; Cantor, G.H.; Dell-John, J.; Chen, C.; Discenza, L.; Menard, K.; Li, A.; Trainor, G.; Vyas, D.; Kramer, R.; Attar, R.M.; Gottardis, M.M. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther., 2009, 8(12), 3341-3349.
45. Desai, J.; Solomon, B.J.; Davis, I.D.; Lipton, L.R.; Hicks, R.; Scott, A.M.; Park, J.; Clemens, P.L.; Gestone, T.A.; Finckenstein, F.G. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. J. Clin. Oncol. (Meeting Abstracts), 2010, 28(15_suppl), 3104.
46. Heinrich, T.; Gradler, U.; Bottcher, H.; Blaukat, A.; Shutes, A. Allosteric IGF-1R Inhibitors. ACS Medicinal Chemistry Letters, 2010, 1(5), 199-203.
47. Goya, M.; Miyamoto, S.; Nagai, K.; Ohki, Y.; Nakamura, K.; Shitara, K.; Maeda, H.; Sangai, T.; Kodama, K.; Endoh, Y.; Ishii, G.; Hasebe, T.; Yonou, H.; Hatano, T.; Ogawa, Y.; Ochiai, A. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res., 2004, 64(17), 6252-6258.
48. Alami, N.; Page, V.; Yu, Q.; Jerome, L.; Paterson, J.; Shiry, L.; Leyland-Jones, B. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res., 2008, 18(6), 487-496.
49. Kido, Y.; Nakae, J.; Accili, D. Clinical review 125: The insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab., 2001, 86(3), 972-979.
50. Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, I.D.; Belfiore, A.; Vigneri, R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell Biol., 1999, 19(5), 3278-3288.
51. Pandini, G.; Vigneri, R.; Costantino, A.; Frasca, F.; Ippolito, A.; Fujita-Yamaguchi, Y.; Siddle, K.; Goldfine, I.D.; Belfiore, A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res., 1999, 5(7), 1935-1944.
52. Belfiore, A.; Pandini, G.; Vella, V.; Squatrito, S.; Vigneri, R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie, 1999, 81(4), 403-407.
53. Garrouste, F.L.; Remacle-Bonnet, M.M.; Lehmann, M.M.; Marvaldi, J.L.; Pommier, G.J. Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells. Endocrinology, 1997, 138(5), 2021-2032.
54. Vezina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo), 1975, 28(10), 721-726.
55. Huang, S.; Bjornsti, M.A.; Houghton, P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther., 2003, 2(3), 222-232.
56. Kim, D.H.; Sarbassov, D.D.; Ali, S.M.; King, J.E.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 2002, 110(2), 163-175.
57. Sarbassov, D.D.; Ali, S.M.; Kim, D.H.; Guertin, D.A.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 2004, 14(14), 1296-1302.
58. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712), 1098-1101.
59. Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 2006, 22(2), 159-168.
60. Busca, R.; Bertolotto, C.; Ortonne, J.P.; Ballotti, R. Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation. J. Biol. Chem., 1996, 271(50), 31824-31830.
61. Grewe, M.; Gansauge, F.; Schmid, R.M.; Adler, G.; Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res., 1999, 59(15), 3581-3587.
62. Gerullis, H.; Ecke, T.H.; Eimer, C.; Heuck, C.J.; Otto, T. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review. Minerva Urol. Nefrol., 2010, 62(4), 411-423.
63. Wolpin, B.M.; Hezel, A.F.; Abrams, T.; Blaszkowsky, L.S.; Meyerhardt, J.A.; Chan, J.A.; Enzinger, P.C.; Allen, B.; Clark, J.W.; Ryan, D.P.; Fuchs, C.S. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol., 2009, 27(2), 193-198.
64. Brevet, M.; Shimizu, S.; Zhou, Q.; Olshen, A.; Zakowski, M.F.; Rusch, V.W.; Ladanyi, M. Effect of EGFR and IGF1R on feedback activation of AKT arising from inhibition of mTOR in malignant pleural mesothelioma (MPM). J. Clin. Oncol. (Meeting Abstracts), 2010, 28(15_suppl), e13607.